Second Trial of Cyclosporin A-Induced Remission in Other Immunosuppressant Therapy-Resistant FSGS Patient.
- Author:
Hee Yeon CHO
1
;
Bum Hee LEE
;
Ju Hyung KANG
;
Il Soo HA
;
Hae Il CHEONG
;
Yong CHOI
Author Information
1. Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea. ychoi@plaza.snu.ac.kr
- Publication Type:Case Report
- Keywords:
Steroid-resistant FSGS;
Cyclosporin A;
Remission;
Renal insufficiency
- MeSH:
Child;
Cyclophosphamide;
Cyclosporine*;
Humans;
Ibuprofen;
Kidney Failure, Chronic;
Kidney Transplantation;
Male;
Nephrotic Syndrome;
Proteinuria;
Recurrence;
Reference Values;
Renal Insufficiency;
Steroids
- From:Journal of the Korean Society of Pediatric Nephrology
2005;9(1):83-90
- CountryRepublic of Korea
- Language:English
-
Abstract:
Focal segmental glomerulosclerosis(FSGS) has been detected in approximately 10% of cases of idiopathic nephrotic syndrome in children, and exhibits a poor response to initial steroid therapy, as well as a higher rate of progression to chronic renal failure and relapse after kidney transplantation. We describe a case of an eleven year-old boy with steroid-resistant FSGS who exhibited a response to a second trial of cyclosporin A(CsA) therapy. At the age of 26 months, this patient was diagnosed with steroid-resistant FSGS. For 9 years, he had undergone a gauntlet of therapies to induce remission; oral steroids, cyclophosphamide, methylprednisolone(mehylPd) pulse therapy, CsA, and ibuprofen therapy. Although these therapies failed to induce remission, the patient's renal function remained in the normal range during the nine years of treatment. At the age of ten years, the patient's proteinuria decreased, and complete remission was attained with a second administration of CsA, coupled with a low dose of oral steroids. This patient continues to receive CsA without relapse. Therefore, our major concern involves the possibility of relapse after the discontinuation of CsA therapy. Our findings in this case suggest that, in cases of refractory FSGS, if renal insufficiency does not emerge, aggressive therapy for the amelioration of proteinuria should be continuously pursued.
